ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Up 11.8% in January

ADMA Biologics, Inc. (NASDAQ:ADMA) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 13,620,000 shares, an increase of 11.8% from the December 31st total of 12,180,000 shares. Based on an average daily volume of 3,500,000 shares, the days-to-cover ratio is currently 3.9 days.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On ADMA Biologics

A number of institutional investors have recently modified their holdings of ADMA. Hollencrest Capital Management acquired a new stake in shares of ADMA Biologics in the 3rd quarter valued at about $30,000. Larson Financial Group LLC acquired a new stake in ADMA Biologics during the third quarter worth about $31,000. GAMMA Investing LLC raised its stake in ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 967 shares during the period. National Bank of Canada FI acquired a new stake in ADMA Biologics during the third quarter worth about $35,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in ADMA Biologics during the third quarter worth about $62,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

ADMA has been the topic of a number of research analyst reports. Raymond James lifted their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright lifted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $16.15 on Friday. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $3.82 billion, a price-to-earnings ratio of 57.68 and a beta of 0.76. The firm’s fifty day simple moving average is $18.10 and its 200 day simple moving average is $17.55. ADMA Biologics has a twelve month low of $5.02 and a twelve month high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. During the same quarter in the previous year, the business posted $0.01 EPS. As a group, equities research analysts expect that ADMA Biologics will post 0.51 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.